Foy Matthew 4
4 · Decibel Therapeutics, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
Foy Matthew
Director10% Owner
Transactions
- Conversion
Common Stock
2021-02-17+458,487→ 458,487 total(indirect: See footnote) - Conversion
Common Stock
2021-02-17+247,324→ 705,811 total(indirect: See footnote) - Conversion
Common Stock
2021-02-17+327,852→ 1,033,663 total(indirect: See footnote) - Purchase
Common Stock
2021-02-17$18.00/sh+150,000$2,700,000→ 1,183,663 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-17−7,119,852→ 0 total(indirect: See footnote)→ Common Stock (458,487 underlying) - Conversion
Series C Preferred Stock
2021-02-17−3,125,000→ 0 total(indirect: See footnote)→ Common Stock (247,324 underlying) - Conversion
Series D Preferred Stock
2021-02-17−1,737,619→ 0 total(indirect: See footnote)→ Common Stock (327,852 underlying)
Footnotes (4)
- [F1]On February 17, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 15.529-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]On February 17, 2021, the Series C Preferred Stock automatically converted into Common Stock on a 12.6352-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F3]On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F4]Held of record by GSK Equity Investments, Limited ("GSK"), an indirect, wholly owned subsidiary of GlaxoSmithKline plc. SR One Capital Management, LP ("S.R. One") is the investment advisor for GSK. Mr. Foy is a partner at S.R. One. Mr. Foy disclaims beneficial ownership of all the shares reported herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein.